A261780 Stock Overview
Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products targeting infectious and chronic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CHA Vaccine Research Institute Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,930.00 |
| 52 Week High | ₩6,100.00 |
| 52 Week Low | ₩2,785.00 |
| Beta | 0.70 |
| 1 Month Change | -5.94% |
| 3 Month Change | -21.02% |
| 1 Year Change | -42.44% |
| 3 Year Change | -61.70% |
| 5 Year Change | n/a |
| Change since IPO | -77.46% |
Recent News & Updates
Is CHA Vaccine Research Institute (KOSDAQ:261780) Using Debt In A Risky Way?
Dec 05
Is CHA Vaccine Research Institute (KOSDAQ:261780) Using Too Much Debt?
Aug 12Shareholder Returns
| A261780 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.5% | 3.0% | 3.4% |
| 1Y | -42.4% | 32.2% | -2.8% |
Return vs Industry: A261780 underperformed the KR Biotechs industry which returned 32.2% over the past year.
Return vs Market: A261780 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
| A261780 volatility | |
|---|---|
| A261780 Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.9% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A261780 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A261780's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Jungsun Yum | www.chavaccine.com |
Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products targeting infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster. The company also develops influenza vaccine, recombinant MBL, TB vaccine, and cancer vaccine.
CHA Vaccine Research Institute Fundamentals Summary
| A261780 fundamental statistics | |
|---|---|
| Market cap | ₩78.32b |
| Earnings (TTM) | -₩4.26b |
| Revenue (TTM) | ₩370.66m |
211.3x
P/S Ratio-18.4x
P/E RatioIs A261780 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A261780 income statement (TTM) | |
|---|---|
| Revenue | ₩370.66m |
| Cost of Revenue | ₩23.93m |
| Gross Profit | ₩346.73m |
| Other Expenses | ₩4.61b |
| Earnings | -₩4.26b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -159.36 |
| Gross Margin | 93.54% |
| Net Profit Margin | -1,149.35% |
| Debt/Equity Ratio | 27.8% |
How did A261780 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 22:43 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CHA Vaccine Research Institute is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.